[Clinical studies on gabapentin in Switzerland]

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Gabapentin is a novel antiepileptic medication.
• It is utilized in the combination therapy for partial seizures.
• Gabapentin was first introduced in Switzerland in January 1995.

Purpose of the Study:

• To describe ongoing clinical studies of gabapentin in Switzerland.
• To evaluate gabapentin's efficacy and tolerance in various therapeutic contexts.
• To assess gabapentin's utility in pediatric partial seizures.

Main Methods:

• Multicenter studies are being conducted internationally.
• An open-label study assesses seizure-free rates with varying gabapentin dosages as add-on therapy.
• Comparative study: Gabapentin efficacy and tolerance versus carbamazepine monotherapy.
• Pediatric study: Evaluating gabapentin for partial seizures in children.

Main Results:

• Ongoing studies are evaluating seizure-free patient numbers under gabapentin add-on therapy.
• Efficacy and tolerance data are being collected for gabapentin compared to carbamazepine.
• Pediatric efficacy for partial seizures is under examination.

Conclusions:

• Gabapentin is under investigation for its role in managing partial seizures.
• Clinical trials are exploring its use as both add-on and monotherapy.
• Further research includes its application in pediatric epilepsy management.